DREAM3R : DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial

Male or<br/>FemaleGender Male or

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Lung<br/>CancersCancer LocationLung

Systemic therapy,Treatment | LungLung,Mesothelioma

Trial Overview Read MoreRead more

This phase III trial is trying to understand whether adding a form of targeted therapy to standard chemotherapy will improve overall survival for patients with malignant pleural mesothelioma.

This trial is treating patients with malignant pleural mesothelioma.

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial

Cooperative Group

Australasian Lung Cancer Trials Group (ALTG)

Commercial Sponsor

PrECOG, LLC & AstraZeneca

Other Non-Commercial Sponsor

University of Sydney


Two thirds of eligible patients will be randomly assigned to receive durvalumab in addition to standard chemotherapy containing pemetrexed and cisplatin. One third of eligible patients will receive chemotherapy alone, followed by observation.

Recruiting Hospitals Read MoreRead more

Olivia Newton-John Cancer Wellness & Research Centre
Ms Samantha Chakar
03 9496 3088

Border Medical Oncology
Ms Nyree Sarakis
02 6064 1493

Goulburn Valley Health
Ms Carole Mott
(03) 5832 3777

PCCTU (Parkville Cancer Clinical Trials Unit) *
Enquiries Line Coordinator
03 8559 7456 (9am-2pm, Mon-Fri)

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.